Ranibizumab outperforms laser in improving diabetic macular edema

08/26/2013 | MedPage Today (free registration)

Data on diabetic macular edema patients showed 49.1% of those on ranibizumab monotherapy attained at least a 5-point improvement in National Eye Institute Visual Functioning Questionnaire 25 composite scores after 12 months, compared with 42.7% of those on ranibizumab plus laser therapy and 30.6% of those on laser-only treatment. However, further analysis is required to determine whether the drug's benefits will be sustained during the three-year study period, researchers reported in JAMA Opthalmology.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI